跳至主要内容
临床试验/EUCTR2011-001314-34-Outside-EU/EEA
EUCTR2011-001314-34-Outside-EU/EEA进行中(未招募)不适用

Randomized, Double-Blind Trial of MP29-02 Nasal SprayCompared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Subjects with Seasonal Allergic Rhinitis

MedPointe Pharmaceuticals0 个研究点目标入组 600 人开始时间: 2011年3月30日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 12-hour reflective Total Nasal Symptom Score (TNSS) of at least 8 out of a possible 12 on screening visit, and a congestion score of 2 or 3 on Day -7
  • 12-hour reflective TNSS of at least 8 on 3 separate symptom assessments during the lead-in period
  • 12-hour reflective nasal congestion score of 2 or 3 recorded on 3 separate symptom assessments during the lead-in period
  • At least 2-year history of SAR during Texas Mountain Cedar season
  • Presence of IgE-mediated hypersensitivity to a Texas Mountain Cedar, confirmed by a positive response to skin prick within the last year
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 43
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 536
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 28

排除标准

  • Presence on nasal examination of any mucosal erosion, nasal ulceration, or nasal septal perforation on screening visit or randomisation visit
  • Nasal surgery or sinus surgery within the previous year
  • Chronic sinusitis with more than 3 episodes per year
  • Patients currently or during the previous 6-months on sublingual immunotherapy
  • Female adolescents who were pregnant or nursing
  • Patients receiving immunotherapy injections and not on stable maintenance regimen for at least 30 days before the first study visit

研究者

相似试验

进行中(未招募)
不适用
Study comparing the effect of a nasal spray combination of azelastine and fluticasone with azelastine nasal spray, fluticasone nasal spray anda nasal spray without active substance in the treatment of patients with hay fever
EUCTR2011-001371-39-Outside-EU/EEAMeda Pharmaceuticals Inc.1,800
进行中(未招募)
不适用
Study comparing the effect of a nasal spray combination of azelastine and fluticasone with azelastine nasal spray, fluticasone nasal spray anda nasal spray without active substance in the treatment of patients with hay fevertreatment of seasonal allergic rhinitisMedDRA version: 13.1Level: LLTClassification code 10039776Term: Seasonal allergic rhinitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2011-001369-42-Outside-EU/EEAMeda Pharmaceuticals Inc.780
进行中(未招募)
不适用
Study comparing the effect of a nasal spray combination of azelastine and fluticasone with azelastine nasal spray, fluticasone nasal spray anda nasal spray without active substance in the treatment of patients with hay fever
EUCTR2011-001370-26-Outside-EU/EEAMeda Pharmaceuticals Inc.780
进行中(未招募)
不适用
Treatment with Iloprost and Integrilin compared to standard care in severe pneumonia patients with severe sepsis.
EUCTR2011-002254-31-FIRigshospitalet, ITA 4131, Department of Intensive care36
进行中(未招募)
1 期
Treatment with Iloprost and Integrilin compared to standard care in severe pneumonia patients with severe sepsis.
EUCTR2011-002254-31-DKRigshospitalet, ITA 4131, Department of Intensive care36